Reduction of the risk of severe COVID-19 due to Omicron compared to Delta variant in Italy (November 2021 - February 2022).

COVID-19 Death Delta variant Hospitalization Omicron variant SARS-CoV-2

Journal

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 05 07 2022
revised: 17 01 2023
accepted: 18 01 2023
pubmed: 29 1 2023
medline: 22 3 2023
entrez: 28 1 2023
Statut: ppublish

Résumé

During 2022, Omicron became the dominant SARS-CoV-2 variant in Europe. This study aims to assess the impact of such variant on severe disease from SARS-CoV-2 compared with the Delta variant in Italy. Using surveillance data, we assessed the risk of developing severe COVID-19 with Omicron infection compared with Delta in individuals aged ≥12 years using a multilevel negative binomial model adjusting for sex, age, vaccination status, occupation, previous infection, weekly incidence, and geographical area. We also analyzed the interaction between the sequenced variant, age, and vaccination status. We included 21,645 cases of SARS-CoV-2 infection where genome sequencing found Delta (10,728) or Omicron (10,917), diagnosed from November 15, 2021 to February 01, 2022. Overall, 3,021 cases developed severe COVID-19. We found that Omicron cases had a reduced risk of severe COVID-19 compared with Delta cases (incidence rate ratio [IRR] = 0.77; 95% confidence interval [CI]: 0.70-0.86). The largest difference was observed in cases aged 40-59 (IRR = 0.66; 95% CI: 0.55-0.79), while no protective effect was found in those aged 12-39 (IRR = 1.03; 95% CI: 0.79-1.33). Vaccination was associated with a lower risk of developing severe COVID-19 in both variants. The Omicron variant is associated with a lower risk of severe COVID-19 compared to infection with the Delta variant, but the degree of protection varies with age.

Identifiants

pubmed: 36708869
pii: S1201-9712(23)00027-9
doi: 10.1016/j.ijid.2023.01.027
pmc: PMC9877142
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

135-141

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Auteurs

Daniele Petrone (D)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy; Department of Statistics, Sapienza University of Rome, Rome, Italy.

Alberto Mateo-Urdiales (A)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy. Electronic address: alberto.mateourdiales@iss.it.

Chiara Sacco (C)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Flavia Riccardo (F)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Antonino Bella (A)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Luigina Ambrosio (L)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Alessandra Lo Presti (A)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Angela Di Martino (A)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Emiliano Ceccarelli (E)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Martina Del Manso (M)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Massimo Fabiani (M)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Paola Stefanelli (P)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Patrizio Pezzotti (P)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

AnnaTeresa Palamara (A)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH